Barclays analyst Peter Lawson downgraded ImmunoGen to Equal Weight from Overweight with a price target of $31, up from $27. The analyst cites the announced acquisition of ImmunoGen by AbbVie for the downgrade. The firm sees a high likelihood of deal closure on time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMGN:
- ImmunoGen downgraded to Equal Weight from Overweight at Barclays
- ImmunoGen downgraded to Hold from Buy at Jefferies
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- ImmunoGen downgraded to Neutral from Buy at Guggenheim
- ImmunoGen downgraded to Market Perform from Outperform at BMO Capital
